Cargando…
The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
OBJECTIVE: To compare the efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in the treatment of patients with cerebral venous sinus thrombosis (CVST), and to provide an appropriate treatment option in these patients. METHOD: This is a randomized double blind...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Riyadh : Armed Forces Hospital
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727621/ https://www.ncbi.nlm.nih.gov/pubmed/26492115 http://dx.doi.org/10.17712/nsj.2015.4.20150375 |
_version_ | 1782411990965157888 |
---|---|
author | Afshari, Daryoush Moradian, Nasrin Nasiri, Freshteh Razazian, Nazanin Bostani, Arash Sariaslani, Payam |
author_facet | Afshari, Daryoush Moradian, Nasrin Nasiri, Freshteh Razazian, Nazanin Bostani, Arash Sariaslani, Payam |
author_sort | Afshari, Daryoush |
collection | PubMed |
description | OBJECTIVE: To compare the efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in the treatment of patients with cerebral venous sinus thrombosis (CVST), and to provide an appropriate treatment option in these patients. METHOD: This is a randomized double blind clinical trial conducted between December 2013 and December 2014. The subjects were selected among patients referred to Neurology Department, Imam Reza Hospital; affiliated to Kermanshah University of Medical Sciences, Kermanshah, Iran. Fifty-two cases of CVST were included in this study and randomly divided into 2 groups. Twenty-six cases received LMWH and the other 26 cases received UFH. The primary outcomes include hospital mortality rate and neurologic deficits as assessed by the National Institutes of Health Stroke Scale (NIHSS). The secondary end point was disability as measured by the Modified Rankin Scale (MRS). RESULTS: We observed the rate of mortality and neurological deficits and disability based on NIHSS, and the MRS did not differ between the 2 groups. CONCLUSION: The efficacy of LMWH and UFH in reduction of neurologic deficit and functional disability in patients with CVST are similar. |
format | Online Article Text |
id | pubmed-4727621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Riyadh : Armed Forces Hospital |
record_format | MEDLINE/PubMed |
spelling | pubmed-47276212016-02-02 The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis Afshari, Daryoush Moradian, Nasrin Nasiri, Freshteh Razazian, Nazanin Bostani, Arash Sariaslani, Payam Neurosciences (Riyadh) Original Article OBJECTIVE: To compare the efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in the treatment of patients with cerebral venous sinus thrombosis (CVST), and to provide an appropriate treatment option in these patients. METHOD: This is a randomized double blind clinical trial conducted between December 2013 and December 2014. The subjects were selected among patients referred to Neurology Department, Imam Reza Hospital; affiliated to Kermanshah University of Medical Sciences, Kermanshah, Iran. Fifty-two cases of CVST were included in this study and randomly divided into 2 groups. Twenty-six cases received LMWH and the other 26 cases received UFH. The primary outcomes include hospital mortality rate and neurologic deficits as assessed by the National Institutes of Health Stroke Scale (NIHSS). The secondary end point was disability as measured by the Modified Rankin Scale (MRS). RESULTS: We observed the rate of mortality and neurological deficits and disability based on NIHSS, and the MRS did not differ between the 2 groups. CONCLUSION: The efficacy of LMWH and UFH in reduction of neurologic deficit and functional disability in patients with CVST are similar. Riyadh : Armed Forces Hospital 2015-10 /pmc/articles/PMC4727621/ /pubmed/26492115 http://dx.doi.org/10.17712/nsj.2015.4.20150375 Text en Copyright: © Neurosciences https://creativecommons.org/licenses/by-nc-sa/3.0/Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. |
spellingShingle | Original Article Afshari, Daryoush Moradian, Nasrin Nasiri, Freshteh Razazian, Nazanin Bostani, Arash Sariaslani, Payam The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis |
title | The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis |
title_full | The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis |
title_fullStr | The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis |
title_full_unstemmed | The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis |
title_short | The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis |
title_sort | efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727621/ https://www.ncbi.nlm.nih.gov/pubmed/26492115 http://dx.doi.org/10.17712/nsj.2015.4.20150375 |
work_keys_str_mv | AT afsharidaryoush theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT moradiannasrin theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT nasirifreshteh theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT razaziannazanin theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT bostaniarash theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT sariaslanipayam theefficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT afsharidaryoush efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT moradiannasrin efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT nasirifreshteh efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT razaziannazanin efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT bostaniarash efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis AT sariaslanipayam efficacyandsafetyoflowmolecularweightheparinandunfractionatedheparininthetreatmentofcerebralvenoussinusthrombosis |